{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:33Z","timestamp":1790842113774,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102410","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:13:52Z","timestamp":1754432032000},"page":"102410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reassessing the Evidence: Is Intensified Therapy Justified in Older Patients with Metastatic Hormone-Sensitive Prostate Cancer?"],"prefix":"10.1016","volume":"23","author":[{"given":"Lorenzo","family":"Dottorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Iaculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico Di","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Vavassori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Rossitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102410_bib0001","first-page":"428","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102410_bib0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2020.12.021","article-title":"Prostate cancer foundation hormone-sensitive prostate cancer biomarker working group meeting summary","volume":"155","author":"Hofmann","year":"2021","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.clgc.2025.102410_bib0003","first-page":"193","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"40","author":"Menges","year":"2022","journal-title":"Urol Oncol: Sem Origin Investigat"},{"issue":"17","key":"10.1016\/j.clgc.2025.102410_bib0004","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/cancers14174149","article-title":"The effect of age on prostate cancer survival","volume":"14","author":"Clark","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2025.102410_bib0005","first-page":"135","article-title":"Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia","volume":"24","author":"Goebell","year":"2024","journal-title":"Exp Rev Antican Therap."},{"issue":"15","key":"10.1016\/j.clgc.2025.102410_bib0006","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102410_bib0007","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.2147\/OTT.S228355","article-title":"Metastatic hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape","volume":"13","author":"Hall","year":"2020","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"10.1016\/j.clgc.2025.102410_bib0008","first-page":"18","article-title":"Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review","volume":"41","author":"Br\u00f6nimann","year":"2024","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102410_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21681805.2020.1851762","article-title":"Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study","volume":"55","author":"Svensson","year":"2021","journal-title":"Scandinav J Urol"},{"issue":"15","key":"10.1016\/j.clgc.2025.102410_bib0010","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2025.102410_bib0011","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102410_bib0012","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102410_bib0013","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in metastatic noncastrate prostate cancer (GETUG-AFU15): a randomised, open-label, phase 3 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102410_bib0014","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone-sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2025.102410_bib0015","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clgc.2025.102410_bib0016","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102410_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102410_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9214","key":"10.1016\/j.clgc.2025.102410_bib0019","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","author":"Group","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clgc.2025.102410_bib0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41391-021-00389-2","article-title":"Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer","volume":"24","author":"Lage","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.clgc.2025.102410_bib0021","first-page":"1874","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"25","author":"Wildiers","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102410_bib0022","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1532-5415.2007.01367.x","article-title":"Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice","volume":"55","author":"Hurria","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clgc.2025.102410_bib0023","first-page":"1645","article-title":"Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment","volume":"9","author":"Caillet","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"2","key":"10.1016\/j.clgc.2025.102410_bib0024","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/annonc\/mdt386","article-title":"An update on a systematic review of the use of geriatric assessment for older adults in oncology","volume":"25","author":"Puts","year":"2014","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102410_bib0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2023.41.6_suppl.90","article-title":"Prognostic role of geriatric assessment (GA) in patients with metastatic prostate cancer (MPCaP) attended in medical oncology","volume":"41","author":"Osorio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102410_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.06.008","article-title":"Evaluating treatment efficacy in metastatic hormone-sensitive prostate cancer patients with visceral disease: A systematic review and network meta-analysis","author":"Flauto","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:25:30Z","timestamp":1757517930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325001107"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102410","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the Evidence: Is Intensified Therapy Justified in Older Patients with Metastatic Hormone-Sensitive Prostate Cancer?","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102410"}}